Therapeutic significance of long noncoding RNAs in estrogen receptor-positive breast cancer.

Autor: Alzahrani AA; Department of Surgery, Taif University, Taif, Saudi Arabia., Saleh RO; Department of Medical Laboratory Techniques, Al-Maarif University College, Al-Anbar, Iraq., Latypova A; Department of Medical and Technical Information Technology, Bauman Moscow State Technical University, Moscow, Russia.; Department of Mathematics and Natural Sciences, Gulf University for Science and Technology, Mishref Campus, Kuwait., Bokov DO; Institute of Pharmacy, Sechenov First Moscow State Medical University, Moscow, Russian Federation.; Laboratory of Food Chemistry, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow, Russian Federation., Kareem AH; College of Health and Medical Technology, Al-Ayen University, Thi-Qar, Thi-Qar, Iraq., Talib HA; College of Agriculture, National University of Science and Technology, Dhi Qar, Dhi Qar, Iraq., Hameed NM; Anesthesia techniques, Al-Nisour University College, Iraq., Pramanik A; Divison of Research and Innovation, School of Applied and Life Sciences, Uttaranchal University, Dehradun, Uttarakhand, India., Alawadi A; College of Technical Engineering, the Islamic University, Najaf, Iraq.; College of Technical Engineering, the Islamic University of Al Diwaniyah, Iraq.; College of Technical Engineering, the Islamic University of Babylon, Iraq., Alsalamy A; College of Technical Engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna, Iraq.
Jazyk: angličtina
Zdroj: Cell biochemistry and function [Cell Biochem Funct] 2024 Apr; Vol. 42 (3), pp. e3993.
DOI: 10.1002/cbf.3993
Abstrakt: About 70% of cases of breast cancer are compromised by Estrogen-positive breast cancer. Through its regulation of several processes, including cell proliferation, cell cycle progression, and apoptosis, Estrogen signaling plays a pivotal role in the genesis and progression of this particular kind of breast cancer. One of the best treatment strategies for treating Estrogen-positive breast cancer is blocking Estrogen signaling. However, patients' treatment failure is mainly caused by the emergence of resistance and metastases, necessitating the development of novel therapeutic targets. Numerous studies have shown long noncoding RNAs (lncRNAs) to play a role in Estrogen-mediated carcinogenesis. These lncRNAs interact with co-regulators and the Estrogen signaling cascade components, primarily due to Estrogen activation. Vimentin and E-cadherin are examples of epithelial-to-mesenchymal transition markers, and they regulate genes involved in cell cycle progression, such as Cyclins, to affect the growth, proliferation, and metastasis of Estrogen-positive breast cancer. Furthermore, a few of these lncRNAs contribute to developing resistance to chemotherapy, making them more desirable targets for enhancing results. Thus, to shed light on the creation of fresh approaches for treating this cancer, this review attempts to compile recently conducted studies on the relationship between lncRNAs and the advancement of Estrogen-positive breast cancer.
(© 2024 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: